<- Go Home
Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Market Cap
$1.3M
Volume
5.5K
Cash and Equivalents
$4.9M
EBITDA
-$34.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
0.00%
52 Week High
$1.49
52 Week Low
$0.00
Dividend
N/A
Price / Book Value
-0.01
Price / Earnings
-0.00
Price / Tangible Book Value
-0.01
Enterprise Value
$4.8M
Enterprise Value / EBITDA
-0.14
Operating Income
-$35.3M
Return on Equity
376.80%
Return on Assets
-181.05
Cash and Short Term Investments
$4.9M
Debt
$8.3M
Equity
-$24.4M
Revenue
$13.0K
Unlevered FCF
-$3.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium